Principal Financial Group
ALLO icon

Principal Financial Group’s Allogene Therapeutics ALLO Stock Holding History

Principal Financial Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,993
Closed -$14.9K – 2188
2025
Q3 		$14.9K Buy
11,993
+1,611
+16% +$1.92K ﹤0.01% 2244
2025
Q2 		$11.7K Buy
+10,382
New +$13.8K ﹤0.01% 2223
2024
Q3 		– Sell
-16,836
Closed -$39.2K – 2230
2024
Q2 		$39.2K Sell
16,836
-13,935
-45% -$41.1K ﹤0.01% 2301
2024
Q1 		$138K Sell
30,771
-3,842
-11% -$16K ﹤0.01% 2235
2023
Q4 		$111K Sell
34,613
-231,541
-87% -$657K ﹤0.01% 2260
2023
Q3 		$844K Buy
266,154
+4,531
+2% +$19.9K ﹤0.01% 1862
2023
Q2 		$1.3M Buy
261,623
+995
+0.4% +$5.38K ﹤0.01% 1810
2023
Q1 		$1.29M Buy
260,628
+9,769
+4% +$62.7K ﹤0.01% 1821
2022
Q4 		$1.58M Buy
250,859
+2,316
+0.9% +$21.4K ﹤0.01% 1802
2022
Q3 		$2.68M Buy
248,543
+7,260
+3% +$98.7K ﹤0.01% 1668
2022
Q2 		$2.75M Buy
241,283
+4,074
+2% +$36.2K ﹤0.01% 1734
2022
Q1 		$2.16M Sell
237,209
-908
-0.4% -$9.46K ﹤0.01% 1851
2021
Q4 		$3.55M Buy
238,117
+97,060
+69% +$1.71M ﹤0.01% 1763
2021
Q3 		$3.63M Sell
141,057
-878
-0.6% -$20.8K ﹤0.01% 1773
2021
Q2 		$3.7M Buy
141,935
+3,607
+3% +$103K ﹤0.01% 1786
2021
Q1 		$4.88M Buy
138,328
+13,726
+11% +$463K ﹤0.01% 1674
2020
Q4 		$3.15M Buy
124,602
+13,894
+13% +$453K ﹤0.01% 1695
2020
Q3 		$4.17M Buy
110,708
+2,611
+2% +$98.4K ﹤0.01% 1525
2020
Q2 		$4.63M Sell
108,097
-27,068
-20% -$979K ﹤0.01% 1460
2020
Q1 		$2.63M Buy
135,165
+752
+0.6% +$17.9K ﹤0.01% 1516
2019
Q4 		$3.49M Sell
134,413
-898
-0.7% -$24.7K ﹤0.01% 1623
2019
Q3 		$3.69M Buy
135,311
+146
+0.1% +$4.16K ﹤0.01% 1599
2019
Q2 		$3.63M Buy
135,165
+76,665
+131% +$2.14M ﹤0.01% 1618
2019
Q1 		$1.69M Sell
58,500
-5,800
-9% -$168K ﹤0.01% 1759
2018
Q4 		$1.73M Buy
+64,300
New +$1.71M ﹤0.01% 1739

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Principal Financial Group's ALLO Position: Q4 2025 in Review

Principal Financial Group sold out of Allogene Therapeutics (ALLO) in Q4 2025, closing a stake of 11,993 shares — an estimated $14.9K sold.

Principal Financial Group first reported a position in ALLO in Q4 2018 and held it in 25 quarters. The position peaked at $4.88M in Q1 2021. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

  • Principal Financial Group reported no remaining Allogene Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Financial Group sold 11,993 Allogene Therapeutics shares in Q4 2025, an estimated $14.9K.
  • Principal Financial Group first reported a position in Allogene Therapeutics in Q4 2018 and held it in 25 quarters.
  • Principal Financial Group's Allogene Therapeutics position peaked at $4.88M in Q1 2021.
  • 172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on Principal Financial Group's 13F filing for Q4 2025, filed 2 Feb 2026.